Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Genome-edited human pluripotent stem cells (hPSCs) have broad applications in disease modeling, drug discovery, and regenerative medicine. We present and characterize a robust method for rapid, scarless introduction or correction of disease-associated variants in hPSCs using CRISPR/Cas9. Utilizing non-integrated plasmid vectors that express a puromycin N-acetyl-transferase (PAC) gene, whose expression and translation is linked to that of Cas9, we transiently select for cells based on their early levels of Cas9 protein. Under optimized conditions, co-delivery with single-stranded donor DNA enabled isolation of clonal cell populations containing both heterozygous and homozygous precise genome edits in as little as 2 weeks without requiring cell sorting or high-throughput sequencing. Edited cells isolated using this method did not contain any detectable off-target mutations and displayed expected functional phenotypes after directed differentiation. We apply the approach to a variety of genomic loci in five hPSC lines cultured using both feeder and feeder-free conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“Ontarget (Doench et al., 2016) and off-target (Hsu et al., 2013) scores greater than 40 (higher is better) were selected whenever possible to increase the performance and specificity of sgRNAs.”
BackgroundGUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · cited 1×
“However, a more comprehensive genome-wide analysis (Kim et al., 2015; Tsai et al., 2015) is required to definitively evaluate off-target editing.”
BackgroundKim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487 · cited 1×
“The mutation introduction or correction was designed to disrupt the PAM site, or tomodify the genomic sequence as close to the ‘‘seed’’ region of the sgRNA (Pattanayak et al., 2013).”
BackgroundChu, V. T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., & Kühn, R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3198 · Cited by 1,210
Maruyama, T., Dougan, S. K., Truttmann, M. C., Bilate, A. M., Ingram, J. R., & Ploegh, H. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3190 · Cited by 1,137 · cited 12×
“Selection conditions that generated approximately 20–80 clones per well (0.3–0.4 mg/mL for BD6-4 in Figure 2C and 0.2–0.3 mg/mL for BD4-18 in Figure 2E) had 10%–36% HDR with concomitant 3%–18% NHEJ, where HDR exceededNHEJ for each condition.”
BackgroundInfluentialRichardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L., & Corn, J. E. (2016) · Nature Biotechnology · doi:10.1038/nbt.3481 · Cited by 1,098
Digenome-seq: Genome-wide profiling of CRISPR-cas9 off-target effects in human cells
Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H. R., Hwang, J., Kim, J.-I., & Kim, J.-S. (2015) · Nature Methods · doi:10.1038/nmeth.3284 · Cited by 992 · cited 1×
“However, a more comprehensive genome-wide analysis (Kim et al., 2015; Tsai et al., 2015) is required to definitively evaluate off-target editing.”
BackgroundEfficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951 · cited 2×
“This limitation is shared by all protocols that employ clonal isolation (Hazelbaker et al., 2017), and may be an even greater concern in protocols that require more than one clonal selection step (Paquet et al., 2016; Shy et al., 2016).”
BackgroundGenome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells
Wu, X., Scott, D. A., Kriz, A. J., Chiu, A. C., Hsu, P. D., Dadon, D. B., Cheng, A. W., Trevino, A. E., Konermann, S., Chen, S., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2889 · Cited by 944 · cited 2×
“The inactivated X chromosome condenses into a compact structure (Maxfield Boumil and Lee, 2001); therefore, it is expected that the Cas9-sgRNA complex will encounter difficulties in recognizing and binding to an inactive X chromosome locus to achieve homozygous editing (Kuscu et al., 2014; Singh et al., 2015; Wu et al…”
BackgroundCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864 · cited 1×
“…of cells expressing high levels of Cas9 via fluorescence (Li et al., 2014; Lonowski et al., 2017; Ran et al., 2013) or cell surface marker (Dever et al., 2016)-linked expression requires cell sorting, which requires cell line-specific optimization, and may lead to cell death in various…”
BackgroundLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845 · cited 2×
“…Cell Reports j Vol. 10 j 642–654 j February 13, 2018 j ª 2017 The This is an open access article under the CC BY-NC-ND license (http://creativ drug selection cassettes (delivered via plasmid or linear double-stranded DNA [dsDNA] donors) to efficiently identify edited clones (Lombardo et al., 2007).”
BackgroundGenome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease
Kuscu, C., Arslan, S., Singh, R., Thorpe, J., & Adli, M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2916 · Cited by 777 · cited 2×
“The inactivated X chromosome condenses into a compact structure (Maxfield Boumil and Lee, 2001); therefore, it is expected that the Cas9-sgRNA complex will encounter difficulties in recognizing and binding to an inactive X chromosome locus to achieve homozygous editing (Kuscu et al., 2014; Singh et al., 2015; Wu et al…”
BackgroundSoldner, F., Laganière, J., Cheng, A. W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L. I., Myers, R. H., Lindquist, S., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.019 · Cited by 728
Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations
Merkle, F. T., Ghosh, S., Kamitaki, N., Mitchell, J., Avior, Y., Mello, C., Kashin, S., Mekhoubad, S., Ilic, D., Charlton, M., et al. (2017) · Nature · doi:10.1038/nature22312 · Cited by 506
Induced Pluripotent Stem Cells Meet Genome Editing
Hockemeyer, D., & Jaenisch, R. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.013 · Cited by 499 · cited 1×
“Such ‘‘engineering in’’ of disease-associated mutations into a putatively WT or normal cell line is desirable to create sets of isogenic cell lines for rigorous study of genotype-phenotype relationships (Hockemeyer and Jaenisch, 2016; Merkle and Eggan, 2013).”
BackgroundSmall molecules enhance CRISPR genome editing in pluripotent stem cells
Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., et al. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.01.003 · Cited by 455
Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411 · cited 1×
“Induced pluripotent stem cells (iPSCs) have had a profound impact on disease modeling, personalized drug screening, and autologous tissue replacement fields (Saha and Jaenisch, 2009).”
BackgroundSelf-citationToward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245 · cited 1×
“Amain advantage of the transient puromycin approach is the ability to rapidly optimize selection conditions for a variety of unique hPSC lines, increasingly collected in large stem cell banks and repositories (Turner et al., 2013).”
BackgroundCas9-chromatin binding information enables more accurate CRISPR off-target prediction
Singh, R., Kuscu, C., Quinlan, A., Qi, Y., & Adli, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv575 · Cited by 217
A Self-restricted CRISPR System to Reduce Off-target Effects
Chen, Y., Liu, X., Zhang, Y., Wang, H., Ying, H., Liu, M., Li, D., Lui, K. O., & Ding, Q. (2016) · Molecular Therapy · doi:10.1038/mt.2016.172 · Cited by 81
Cited by
Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications
Liu, G., David, B. T., Trawczynski, M., & Fessler, R. G. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09935-x · Cited by 519
Moradi, S., Mahdizadeh, H., Šarić, T., Kim, J., Harati, J., Shahsavarani, H., Greber, B., & Moore, J. B. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1455-y · Cited by 287
Detection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing
Weisheit, I., Kroeger, J. A., Malik, R., Klimmt, J., Crusius, D., Dannert, A., Dichgans, M., & Paquet, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107689 · Cited by 125
Reifschneider, A., Robinson, S., van Lengerich, B., Gnörich, J., Logan, T., Heindl, S., Vogt, M. A., Weidinger, E., Riedl, L., Wind, K., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2021109108 · Cited by 89
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Self-citation
Metadata
- Authors
- Steyer, B., Bu, Q., Cory, E., Jiang, K., Duong, S., Sinha, D., Steltzer, S., Gamm, D., Chang, Q., & Saha, K.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 10
- Issue
- 2
- Pages
- 642-654
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W2781815848
- Cited by
- 69
- References
- 21
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.